Nestmedics flagship Product Pregnabit is a mobile medical device that combines a telemedical cardiotocography unit (teleCTG) with expert remote analysis of CTG readouts by qualified medical personnel
All
Team
Company
Patients
Physicians
Hospital
Partners
Mission
Innovation Details
Investor Info
Due Diligence Docs
Supporters
Comments
Updates
About our project
The problem we solve: Doctors/clinics:
-Shortage of fundamental services
-Lack of time and attention
-Low reliability of analysis due to episodic, reactive and unconnected treatment
Expecting Mothers:
-Loss of time away from work and childcare
-Personal anxiety and stress
-Lack of continuous support
-Fear of frequent hospital visits due to infection risks (aggravated by COVID-19)
About our solution:
Product Benefits:
-Small and easy to handle
-Reviewing of data history and real-time insight in current data stream
-Secure data cloud storage
-High reliability of information/ measurement
-Easy „Plug and play” (no setup needed)
-Early detection of potential complications
Patient Benefits:
- Safety & Certainty
- Stress minimization & Comfort
- Enable rapid decision making
-Reduction of pregnancy related absence from work
Doctors and Midwives Benefits:
-Additional income
-Full and remote patient history access
-Reduction of queues and increased doctor availability
-USP to other obstetrics practices
Overall:
1. More safety & convenience
2. Less cost & hassle
3. Better clinical
outcome
Progress to
date:
Nestmedic is in the last stages of finalizing their next Product Pregnabit®Pro and start a global scalable sales campaign in the USA after FDA approval.
36 customers and 115 devices currently operating on the market with over 12 000 tests in Poland and in Europe.
Pregnabit has become a very valuable solution during the global COVID-19 pandemic: Over 70 new contracts in B2C model in Q2/2020 and an increase of 257% compared to Q1.
Hospitals, private healthcare, insurers and midwives appreciate Pregnabit: limits visits and hospitalizations of pregnant women.
Various Venture Funds and Private Equity companies believe in Nestmedic’s business model and have invested EUR 3 million.
Additionally, a grant of EUR 850k from the European Union has been received to boost research and development.
Funding needed for acceleration of geographical expansion with access to over 6 million potential end-users* in the EU and especially in the US after FDA approval.
About Our Team
Creator: Nico Konrad
Location: Berry Islands
Education: University of Mannheim - M.Sc.
Bio: I am convinced of PhD management with many years of experience in
-managing production, service and technology companies in the medical industry
-35 years experience in founding/ running/ managing IT companies & creating IT solutions.
-managing and developing telemedicine products in companies such as InfoScan,Cardio.link and EFM
-10 years of experience in quality and regulations for medical devices at BD, PRO-PHARM and USP.
Title: Investor Relations Manager
About Team Members
Jacek Gnich
CEO, BA Biography: Chairman of the Management Board w Nestmedic S.A.
A financier by education.
Many years of experience in managing production, service and technology companies in the medical industry such as IMPAQ, Infoscan and Impera Capital.
He specializes in strategic, financial and operational management.
Title: CEO Advanced Degree(s): BA LinkedIn:https://www.linkedin.com/in/gnich-jacek-21764417/
About Our Company
Nestmedic S.A.
Location: ul. Gwia?dzista 15a lok. 410 Warsaw, MZ 01656 PL
For parents: Why is it worth using the Pregnabit CTG telemedicine system?
It is possible to safely carry out a CTG monitoring on your own, almost anywhere – at home, on vacation, during the weekend.
Should any threat be recognized, a prompt and decisive actions are taken by the medical telemonitoring centre.
User-friendliness of a professional CTG, which is an intuitive and small machine.
Ability to access online current and historical CTG tests, both by the patient and the doctor or midwife.
Reducing to minimum the need of doing CTG examinations in medical centers resulting in reducing travelling and queuing times.
Convenience, comfort, intimacy and the opportunity to participate in the tests of our loved ones.
How We Help Physicians
For medical staff: Why is it worth using the Pregnabit CTG telemedicine system?
Possibility of continuous remote monitoring of patients in the third trimester of pregnancy,
Access to a qualified and experienced team of experts at the Medical Telemonitoring Center
On-line access to current and historical patient's CTG tests and results,
Comfortable diagnosis of CTG for patients, also in home conditions,
Opportunity to stand out from the competitive offices / clinics by offering an innovative service/ USP to other obstetrics practices
Additional income
Reduction of queues and increased doctor availability
How We Help Hospitals
For medical staff: Why is it worth using the Pregnabit CTG telemedicine system?
Possibility of continuous remote monitoring of patients in the third trimester of pregnancy,
Access to a qualified and experienced team of experts at the Medical Telemonitoring Center
On-line access to current and historical patient's CTG tests and results,
Comfortable diagnosis of CTG for patients, also in home conditions,
Opportunity to stand out from the competitive offices / clinics by offering an innovative service/ USP to other obstetrics practices
Additional income
Reduction of queues and increased doctor availability
How We Help Partners
For medical staff: Why is it worth using the Pregnabit CTG telemedicine system?
Possibility of continuous remote monitoring of patients in the third trimester of pregnancy,
Access to a qualified and experienced team of experts at the Medical Telemonitoring Center
On-line access to current and historical patient's CTG tests and results,
Comfortable diagnosis of CTG for patients, also in home conditions,
Opportunity to stand out from the competitive offices / clinics by offering an innovative service/ USP to other obstetrics practices
Additional income
Reduction of queues and increased doctor availability
Innovation Details
Intellectual Property Summary
Nestmedic‘s Patent application no. P.400597 "Method for monitoring fetal health and device for monitoring fetal health“
Integration between the device and a properly functioning teleCTG Monitoring Centre
Distribution of teleCTG device and CTG readout analysis services in multiple countries
Clinical Information
Pregnabit has already achieved to be registered as a certified medical device (CE certified)
Regulatory Status
FDA approval expected soon in order to start USA expansion in 1stQ 2021
How we will use the funds raised
Investments needed for
-Acceleration of geographical expansion with access to over 6 million potential end-users in the EU and especially in the US after FDA approval
-FDA approval process plus initial marketing in the US
-Pregnabit Pro development of hardware and software with the following features
•Access to the patient’s account by several subjects (clinics, doctors)
•Several business structures on one central Telemedical Platform
•Advanced Pulse FHR & TOCO probes of (Philips comparable) quality
•Audio processing module offering exciting sound experience for the mother
•Adjustment to GSM standards for different markets and countries
•Cybersecurity level demanded by western medical institutions
•Computing power easily scalable to eventually growing data traffic
•Documents and effects facilitating the FDA certification process
•Own a computer module for the examination data analysis included
•Integrated tools for devices’ logistics, remote technical supervision etc.
•Graphically attractive and social-media-ready patient’s module
Thank You
Our goal is to be with expecting mothers, giving them the chance to monitor the health of their child anywhere and any time.
Investor Info
Market Size
"70% prefer using a digital solution to monitor their health metrics at home.“- McKinsey & Company
"Personalized Technology will upend the Doctor Patient Relationship“ - Harvard Business Review
"80 percent of the things doctors do today will be done by machines” - Vinod Khosla: billionaire investor
"From USD 111.4 billion in 2019, the global digital health market is predicted to grow to USD 510.4 billion by 2025, registering a CAGR of 29.0% during the forecast period (2020–2025)” - Zion Research, July 2018
"The cumulative costs of childbirth is estimated at well over USD 50 billion annually in the US alone. - The New York Times, June 2013
"540,000 babies are annually born preterm in the US alone with a total annual burden of more than USD 26 billion. - The National Academy of Medicine
Projected 3 Year Growth
Revenue Model
By providing the medical device and access to the analysis platform to doctors, clinics/hospitals, distributors (B2B) or directly to pregnant women (B2C) for a compensation of
- €3999 up-front + €49-99 monthly or
-24 monthly installments payment of €199 + €99 monthly
-Rental only for patients €99 / 2 weeks
Competitors
Pregnabit outperforms the competition in tech and user-friendliness
Due Diligence Docs
Please note that access to the company's confidential materials is limited. Click this button to request access from the Company and its representatives.
An amazing medical device dedicated to pregnant women! During the pandemic, telemedicine is very important as it helps patients stay at home and still remain under medical supervision.
Help us find best new ideas to fund by telling us what you think. Your feedback goes
straight to the team behind this project in private, so tell them what you really think.
I am convinced of PhD management with many years of experience in
-managing production, service and technology companies in the medical industry
-35 yea...
Nestmedics flagship Product Pregnabit is a mobile medical device that combines a telemedical cardiotocography unit (teleCTG) with expert remote analysis of CTG readouts by qualified medical personnel
Thank you for visiting!
This area is for community members only. Please signin or signup and join our global community of people who care about medical innovation.
Progress to
date:
</p>
<p>Reference letters from specialists in gynecology, obstetrics and telemedicine</p>
</p>
</div>
<div class=)
